In a new job – September 14, 2026
Danish biotech Initiator Pharma has appointed Annette Säfholm, PhD, as Chief Operating Officer (COO) and a member of the company’s management team, strengthening its business development and operational capacity as it approaches topline data from its Phase IIa study of pudafensine in vulvodynia.
In a new job – September 14, 2026
AcuCort has appointed Carl Frisk as Strategic Alliance Manager, where he will be responsible for the company’s commercial partnerships and the development of its partner network across all markets.
Sweden – September 14, 2026
Sweden’s general election on 13 September delivered a razor-thin result, with the Social Democrat-led opposition holding an apparent one-seat edge over PM Ulf Kristersson’s right-wing coalition as counting continues — leaving open the fate of an unusually broad cross-party consensus on pharmaceutical policy reform that emerged during the campaign.
Pharma Business – September 14, 2026
The US FDA has granted Orphan Drug Designation to Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for the treatment of endogenous Cushing’s syndrome, adding to a growing list of rare-disease designations for the candidate across three regions.
Pharma Business – September 14, 2026
Novo Nordisk has unveiled a rebrand centred on the tagline “Lasting Health Starts Now” and a shortened public-facing name, “Novo,” alongside a new set of cultural principles called “The Novo Way” aimed at increasing focus and speed across the organisation.
Funding – September 14, 2026
Eleven Swedish research groups, six of them in life science, have been awarded the new Knut and Alice Wallenberg AI Consultancy Grant, giving them access to dedicated AI expertise to accelerate their projects.

Opinion & debate
Clinical Trials – September 14, 2026
ResoTher Pharma has reported promising Phase 2a results for its cardioprotective drug candidate RTP-026, moving the company a step closer to a key efficacy trial and a potential pharma partnership or sale.
Clinical Trials – September 9, 2026
In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.
Clinical Trials – September 8, 2026
A post-hoc analysis of SynAct Pharma’s Phase 2b ADVANCE study confirms earlier positive results for resomelagon in rheumatoid arthritis (RA), and the company now plans to discuss Phase 3 trial design with the FDA in Q4 2026.
Clinical Trials – September 2, 2026
The company has completed the eight-week treatment period for all patients in its pivotal Phase III HEEALING1 study of linaprazan glurate in erosive gastroesophageal reflux disease (GERD), with topline results now expected in the fourth quarter of 2026.
Clinical Trials – August 31, 2026
AstraZeneca and partner Amgen have reported that Tezspire (tezepelumab) met both co-primary and all key secondary endpoints in the Phase III CROSSING trial in eosinophilic esophagitis (EoE), positioning the anti-TSLP antibody for a potential new indication beyond its existing approvals in severe asthma and chronic rhinosinusitis with nasal polyps.
Clinical Trials – August 31, 2026
Faron Pharmaceuticals has announced that the first patient has been enrolled in the BEXAR trial, testing its lead candidate bexmarilimab in combination with chemotherapy as a first-line treatment for metastatic soft-tissue sarcoma.
PharmaRelations
Stillingen er 100 % remote med en forventet arbejdsbelastning på ca. 0-20 timer pr. måned, afhængigt af projektbehov.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
Micrel Medical Device
On behalf of Micrel Medical Devices, we are looking for an ambitious and commercially driven Area Sales Manager to develop and grow the Danish market in a newly established position.
PharmaRelations
Lead strategy, consulting and business growth across the Nordic Life Science market.
Daiichi Sankyo Nordics
Now, we’re looking for a senior HEOR Manager with a solid HTA toolbox who can help secure and expand access to groundbreaking oncology treatments for patients in the Nordics. You will join Daiichi Sankyo, driven by more than 120 years of innovation and a deep global commitment to improving lives.
In a new job – September 4, 2026
SmiLe Venture Hub is strengthening its board with three new members, bringing perspectives from the global life science industry, Sweden’s wider innovation system, and academia.
In a new job – September 4, 2026
Henriette Mersebach has more than 20 years of experience in global drug development, R&D strategy, and enterprise leadership.
In a new job – September 2, 2026
Icelandic generic drug manufacturer Coripharma has appointed Dadi Oskarsson as Director of Supply Chain Operations, adding him to the company’s Executive Management Team.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – June 14, 2026
Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.
Profiles in Business – September 9, 2026
After a full career building life science communities and now approaching something akin to retirement – meaning only cherry-picking the projects that appeal to him – French-born Olivier Duchamp-Giudicelli reflects on the accidental advent of NLSDays in 2014, and how partnering and dealmaking have changed over the years.
Profiles in Business – August 26, 2026
Successful businessman and former chairman of AstraZeneca, Leif Johansson, has accumulated vast experience and knowledge about international competition, leadership, business development, and entrepreneurship, not least when it comes to science-driven industries like the life science industry.
Europe – July 13, 2026
Spanish biochemist and molecular biologist Salvador Aznar Benitah’s research focuses on how adult stem cells function in normal conditions, aging, and cancer, with particular interest in epigenetics, circadian rhythms, and the mechanisms that allow certain cancer cells to initiate metastasis.
Business article – September 11, 2026
The ongoing struggle in the Nordic countries to keep prescription drug prices affordable without shutting out innovative, more expensive therapies continues to frustrate pharmaceutical companies as the introduction of new drugs to the region slows.
Clinical Trials – September 9, 2026
In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.
Collaboration – September 8, 2026
Vienna-based HeartBeat.bio and Stockholm-based Cubase Bio have been awarded roughly EUR 1 million in Eurostars funding to develop a 3D spatial profiling method for studying myocardial fibrosis and heart failure, combining human cardiac organoids with true 3D spatial transcriptomics technology.
MedTech Business – September 9, 2026
Glycorex Transplantation has agreed a distribution deal with Grupo VIDA for its Glycosorb ABO technology in Brazil, as part of the Swedish medtech company’s continued market expansion.
MedTech Business – September 7, 2026
Neola Medical has been granted Breakthrough Device Designation by the US FDA for Neola, its non-invasive lung monitor for preterm babies, designed to give early warning of life-threatening lung collapse.
MedTech Business – September 7, 2026
Bioretec has received FDA 510(k) clearance for ActivaScrew Cannulated COM, a new bioabsorbable compression screw that expands its Activa implant portfolio into the US market.
Biotech Business – September 4, 2026
Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible Canadian patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, BioArctic’s partner Eisai announced.
Biotech Business – September 4, 2026
The company has completed a directed share issue as it approaches proof-of-concept data from its Phase IIa study in chronic kidney disease with anemia, expected around the turn of the year.
Biotech Business – September 1, 2026
Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible Canadian patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, BioArctic’s partner Eisai announced. The Swedish biotech invented the antibody and holds commercialisation rights to it in the Nordic region.
Science News – September 14, 2026
A large population study using NADMED’s redox metabolite testing platform has established healthy reference ranges for NAD and glutathione, two key drivers of cellular energy metabolism, and identified distinct disease-related alterations in both from a single blood sample.
Science News – September 8, 2026
Researchers at the University of Gothenburg have developed a treatment for acute myeloid leukemia that forces cancer cells to run at full throttle while cutting off their energy supply, driving them to burn out and die from the stress. The first study in mice shows highly promising results.
Science News – September 7, 2026
Ada Yonath, the 2009 Nobel laureate in Chemistry, died on August 31, 2026, at the age of 87. She was one of the first Nobel Prize laureates I interviewed as a new editor at Nordic Life Science – and the first I met in person, over an interview at the Grand Hotel in Stockholm. Yonath, who in 2009 became the first woman in 45 years to win the Nobel Prize in Chemistry, spoke to me about her curiosity, polar bears, extremely durable bacteria from the Black Sea, and her passion for science.
Upcoming events
This site uses cookies